Astellas Pharma Inc. (ALPMF)
OTCMKTS
· Delayed Price · Currency is USD
10.04
0.00 (0.00%)
Mar 11, 2025, 4:00 PM EST
Astellas Pharma Employees
Astellas Pharma had 14,754 employees as of March 31, 2024. The number of employees increased by 270 or 1.86% compared to the previous year.
Employees
14,754
Change (1Y)
270
Growth (1Y)
1.86%
Revenue / Employee
$805,144
Profits / Employee
-$24,757
Market Cap
17.55B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 109 |
| Longduoduo Company | 49 |
Astellas Pharma News
- 6 days ago - Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing - PRNewsWire
- 13 days ago - Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize - PRNewsWire
- 27 days ago - U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - PRNewsWire
- 4 weeks ago - Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Benzinga
- 4 weeks ago - Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) - Benzinga
- 4 weeks ago - Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan - PRNewsWire